Granules India Ltd (BOM:532482)

Q4 2025 Granules India Ltd Earnings Call Transcript

May 28, 2025 / 11:30 AM GMT

Release Date Price: ₹522.05 (-1.29%)

Transcript

Key Points

Positve

Granules India Ltd (BOM:532482) reported a 2% revenue growth in Q4 FY25 compared to the same quarter last year, with a 5% increase from Q3 FY25.
The company achieved a gross margin improvement, with Q4 FY25 gross margin at 63.4%, up by 333 basis points from Q4 FY24.
Granules India Ltd (BOM:532482) has made significant progress in its R&D efforts, with a 20% increase in R&D investment, leading to a robust pipeline of 127 dossiers filed across various regions.
The company is strategically expanding into high-growth areas such as oncology and peptide therapeutics, with the acquisition of Sen Chemicals marking a formal entry into complex peptide therapeutics.
Granules India Ltd (BOM:532482) has received a core rating from Ecovi, placing it in the top 5% of pharmaceutical companies globally in its first corporate-level assessment, highlighting its commitment to sustainability.

Negative

The FDA issued a warning letter to Granules India Ltd (BOM:532482) for its Gagillapur facility, which may temporarily impact the FDA's review of pending product submissions.
Ongoing remediation measures at the Gagillapur facility have resulted in a slowdown of operations, impacting Q4 output and expected to continue for another quarter or two.
Professional expenses have increased due to consultancy fees for remediation of US FDA observations, impacting EBITDA margins.
The company's European sales have declined, primarily due to reduced demand for paracetamol API, which was a significant driver in the region.
Granules India Ltd (BOM:532482) faces challenges in diversifying its geographical revenue mix, with North America accounting for a significant portion of total revenues.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

GRAN.NS - Granules India Ltd
Q4 2025 Granules India Ltd Earnings Call
May 28, 2025 / 11:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to the Granuus India Limited Q4 525 earnings conference call. As a reminder, all participant lines will be in the list only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing start then 0 on your touchtone phone. Please note that this conference has been recorded. I now hand the insurance over to Ms. Praji Andre from MUFG Investor relations team.

Thank you and over to you, ma'am.

--------------------------------------------------------------------------------
Unidentified_2 [2]
------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.